Economic value of dengue vaccine in Thailand

Bruce Y. Lee, Diana L. Connor, Sarah B. Kitchen, Kristina M. Bacon, Mirat Shah, Shawn T. Brown, Rachel R. Bailey, Yongjua Laosiritaworn, Donald S Burke, Derek A.T. Cummings

Research output: Contribution to journalArticlepeer-review

Abstract

With several candidate dengue vaccines under development, this is an important time to help stakeholders (e.g., policy makers, scientists, clinicians, and manufacturers) better understand the potential economic value (cost-effectiveness) of a dengue vaccine, especially while vaccine characteristics and strategies might be readily altered. We developed a decision analytic Markov simulation model to evaluate the potential health and economic value of administering a dengue vaccine to an individual (≤ 1 year of age) in Thailand from the societal perspective. Sensitivity analyses evaluated the effects of ranging various vaccine (e.g., cost, efficacy, side effect), epidemiological (dengue risk), and disease (treatment-seeking behavior) characteristics. A ≥ 50% efficacious vaccine was highly cost-effective [< 1x per capita gross domestic product (GDP) ($4,289)] up to a total vaccination cost of $60 and cost-effective [< 3x per capita GDP ($12,868)] up to a total vaccination cost of $200. When the total vaccine series was $1.50, many scenarios were cost saving.

Original languageEnglish (US)
Pages (from-to)764-772
Number of pages9
JournalAmerican Journal of Tropical Medicine and Hygiene
Volume84
Issue number5
DOIs
StatePublished - May 2011
Externally publishedYes

ASJC Scopus subject areas

  • Parasitology
  • Virology
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Economic value of dengue vaccine in Thailand'. Together they form a unique fingerprint.

Cite this